Place of care and costs associated with acute episodes and remission in schizophrenia

被引:0
|
作者
McIntyre, Roger S. [1 ]
Higa, Sara [2 ]
Doan, Quan, V [3 ]
Amari, Diana T. [3 ]
Mercer, Daniel [3 ]
Gillard, Patrick [2 ]
Harrington, Amanda [2 ]
机构
[1] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[2] AbbVie, Irvine, CA USA
[3] Genesis Res, Hoboken, NJ USA
来源
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2023年 / 29卷 / 05期
关键词
ANTIPSYCHOTIC MEDICATION; ECONOMIC BURDEN; ATYPICAL ANTIPSYCHOTICS; NONADHERENCE; PREDICTORS; ADHERENCE; RELAPSE;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Schizophrenia imposes significant economic burden on patients, families, caregivers, and society. To our knowledge, place of care and associated costs of acute schizophrenia episodes have not been well characterized.OBJECTIVE: To describe the care settings and costs associated with likely acute episodes and untreated remission periods among patients with schizophrenia. METHODS: Adults with schizophrenia were identified using the IBM MarketScan Commercial and Medicare Supplemental databases (2009-2018); claims for capitated benefits plans were excluded. Acute episode index date was defined as at least 1 inpatient schizophrenia claim or outpatient schizophrenia claim (frequency of claim dependent on visit type, such as hospitalization, emergency department, private practice, clinic, urgent care, or labora-tory). Mental health-related medical costs (health plan+patient) associated with acute episodes were collected over a 2-month follow-up period and stratified by setting (inpatient vs outpatient); acute episode data were reported in subgroups of patients without or with prior clozapine use, as an indication of disease severity. Remission index date was defined as at least 1 outpa-tient claim with a schizophrenia diagnosis with no acute episode and no oral or inject-able antipsychotic therapy. Remission costs were assessed over a 3-month period. All data were analyzed descriptively.RESULTS: A total of 14,824 patients with schizophrenia met criteria for an acute episode (12,896 [87.0%] without prior clo-zapine use; 1,427 [9.6%] with prior clozapine use). Most acute episodes were treated in an outpatient setting (all patients, 76.3%; without prior clozapine use, 74.5%; with prior clozapine use, 87.1%). When treated inpatient, mean (SD) episode medical costs were $17,045 ($28,101) for all patients, $16,060 ($22,786) for those without prior clozapine use, and $22,827 ($55,860) for those with prior clozapine use. When treat-ed outpatient, mean (SD) medical costs for acute episodes were $2,478 ($6,961) for all patients, $2,609 ($7,068) for those without prior clozapine use, and $1,770 ($6,560) for those with prior clozapine use. For all patients with acute episodes, regardless of clozapine use, patient-incurred out-of-pocket costs were approximately 30% of total medical costs. For an untreated period of remission, 6,950 patients with schizophrenia met criteria. Total medical costs were $2,399 for these patients over a 3-month period.CONCLUSIONS: The majority of acute schizophrenia episodes were treated in the outpatient setting. For episodes that required inpatient care, inpatient episodes were approximately 7 times more costly than episodes treated in outpatient-only settings. For acute episodes and remission periods, health plans covered most costs; however, there were additional patient -incurred out-of-pocket costs.
引用
收藏
页码:499 / 508
页数:10
相关论文
共 50 条
  • [21] Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)
    Mejia-Arangure, Erendira
    Reyes-Lopez, Alfonso
    Enrique Juarez-Villegas, Luis
    Olaf Hernandez-Olivares, Yosef
    Daniel Saucedo-Campos, Alberto
    Hernandez-Pliego, Gabriela
    Martinez-Valverde, Silvia
    Barajas-Nava, Leticia A.
    Garduno-Espinosa, Juan
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [22] Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)
    Eréndira Mejía-Aranguré
    Alfonso Reyes-López
    Luis Enrique Juárez-Villegas
    Yosef Olaf Hernández-Olivares
    Alberto Daniel Saucedo-Campos
    Gabriela Hernández-Pliego
    Silvia Martínez-Valverde
    Leticia A. Barajas-Nava
    Juan Garduño-Espinosa
    BMC Health Services Research, 22
  • [23] Cytokine profiles in bipolar affective disorder during acute episodes and in remission
    Remlinger-Molenda, A.
    Wojciak, P.
    Kostrzewa, A.
    Karczewski, J.
    Wiktorowicz, K.
    Rybakowski, J. K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S415 - S416
  • [24] CLAIMS-BASED APPROACH TO DEFINING EPISODES OF CARE ASSOCIATED WITH ACUTE RENAL COLIC
    Pate, Wesley R.
    Li, Lang
    Scales, Charles D.
    Watson, James T.
    Kavee, Andrew
    Friedlander, David F.
    JOURNAL OF UROLOGY, 2024, 211 (05): : E666 - E666
  • [25] Schizophrenia patients with cognitive deficits: Costs and factors associated with costs
    Patel, A
    Everitt, B
    Knapp, M
    Reeder, C
    Wykes, T
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 274 - 274
  • [26] Prospective study of the costs of care for patients with schizophrenia
    de Castella, AR
    Fitzgerald, PB
    Filia, K
    Montgomery, W
    Kulkarni, J
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 556 - 556
  • [27] A TYPOLOGY OF CARE EPISODES EXPERIENCED BY PEOPLE WITH SCHIZOPHRENIA IN AN ENGLISH TOWN
    COTTERILL, L
    THOMAS, R
    SOCIAL SCIENCE & MEDICINE, 1993, 36 (12) : 1587 - 1595
  • [28] A Conceptual Model for Episodes of Acute, Unscheduled Care
    Pines, Jesse M.
    Lotrecchiano, Gaetano R.
    Zocchi, Mark S.
    Lazar, Danielle
    Leedekerken, Jacob B.
    Margolis, Gregg S.
    Carr, Brendan G.
    ANNALS OF EMERGENCY MEDICINE, 2016, 68 (04) : 484 - 491
  • [29] Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
    Maloney, Ann E.
    Sikich, Linmarie
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 749 - 766
  • [30] Factors associated with prior acute pancreatitis episodes
    Zhu, Xiangyu
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (10) : 1366 - 1366